Table 4.
Description of the study population with review A status (with a total patient population of 5298) by cohort until April 01, 2022
| Variable | N1 | Statistic | HAP, N = 544 | POP, N = 2346 | SÜP, N = 1837 |
|---|---|---|---|---|---|
| Age (numeric) | 4727 | Median (IQR) | 57 (47, 65) | 46 (31, 57) | 56 (42, 68) |
| Age (categorical) | 4727 | ||||
| < 18 | n (%) | 0 (0%) | 0 (0%) | 50 (2.7%) | |
| 18–29 | n (%) | 33 (6.1%) | 501 (21%) | 138 (7.5%) | |
| 30–39 | n (%) | 51 (9.4%) | 446 (19%) | 205 (11%) | |
| 40–49 | n (%) | 83 (15%) | 360 (15%) | 280 (15%) | |
| 50–59 | n (%) | 156 (29%) | 608 (26%) | 368 (20%) | |
| 60–69 | n (%) | 128 (24%) | 260 (11%) | 379 (21%) | |
| 70–79 | n (%) | 69 (13%) | 140 (6.0%) | 255 (14%) | |
| 80+ | n (%) | 24 (4.4%) | 31 (1.3%) | 162 (8.8%) | |
| Gender | 4726 | ||||
| Female | n (%) | 174 (32%) | 1305 (56%) | 723 (39%) | |
| Male | n (%) | 370 (68%) | 1040 (44%) | 1114 (61%) | |
| Non-binary | n (%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| Missing or review A pending | n | 0 | 1 | 0 | |
| Smoking (past or current smoker) | 3867 | ||||
| Yes | n (%) | 28 (6.8%) | 1068 (49%) | 128 (9.9%) | |
| No | n (%) | 381 (93%) | 1100 (51%) | 1162 (90%) | |
| Missing or review A pending | n | 135 | 178 | 547 | |
| Alcohol | 2433 | ||||
| Never | n (%) | 0 (NA%) | 183 (13%) | 516 (50%) | |
| Up to 4 times monthly | n (%) | 0 (NA%) | 676 (48%) | 377 (36%) | |
| Multiple times weekly | n (%) | 0 (NA%) | 536 (38%) | 145 (14%) | |
| Missing or review A pending | n | 544 | 951 | 799 | |
| Obesity at inclusion (BMI ≥ 30 kg/m2) | 4169 | ||||
| No | n (%) | 311 (65%) | 1758 (76%) | 900 (66%) | |
| Yes | n (%) | 167 (35%) | 566 (24%) | 467 (34%) | |
| Missing or review A pending | n | 66 | 22 | 470 | |
| SARS-CoV-2 vaccined | 3581 | ||||
| Yes | n (%) | 93 (19%) | 1189 (55%) | 459 (49%) | |
| No | n (%) | 393 (81%) | 965 (45%) | 482 (51%) | |
| Missing or review A pending | n | 58 | 192 | 896 | |
| In-patient ever | 4161 | ||||
| Yes | n (%) | 544 (100%) | 170 (7.3%) | 1120 (88%) | |
| No | n (%) | 0 (0%) | 2172 (93%) | 155 (12%) | |
| Missing or review A pending | n | 0 | 4 | 562 | |
| Intensive stay ever | 3997 | ||||
| Yes | n (%) | 208 (38%) | 36 (1.5%) | 367 (33%) | |
| No | n (%) | 336 (62%) | 2301 (98%) | 749 (67%) | |
| Missing or review A pending | n | 0 | 9 | 721 | |
| Covid-associated oxygenation | 4619 | ||||
| Invasive/non-invasive ventilation | n (%) | 141 (26%) | 17 (0.7%) | 299 (17%) | |
| O2-therapy only | n (%) | 260 (48%) | 93 (4.0%) | 746 (43%) | |
| No assistance | n (%) | 142 (26%) | 2222 (95%) | 699 (40%) | |
| Missing or review A pending | n | 1 | 14 | 93 | |
| Extracorporeal membrane oxygenation (ECMO) | 4047 | ||||
| Yes | n (%) | 60 (13%) | 1 (<0.1%) | 47 (3.8%) | |
| No | n (%) | 417 (87%) | 2334 (100%) | 1188 (96%) | |
| Missing or review A pending | n | 67 | 11 | 602 | |
| Chronic cardiovascular disease | 3842 | ||||
| Yes | n (%) | 269 (50%) | 601 (29%) | 622 (50%) | |
| No | n (%) | 265 (50%) | 1456 (71%) | 629 (50%) | |
| Missing or review A pending | n | 10 | 289 | 586 | |
| Chronic lung disease | 4013 | ||||
| Yes | n (%) | 109 (21%) | 425 (19%) | 235 (19%) | |
| No | n (%) | 417 (79%) | 1822 (81%) | 1005 (81%) | |
| Missing or review A pending | n | 18 | 99 | 597 | |
| Chronic kidney disease | 4088 | ||||
| Yes | n (%) | 88 (17%) | 8 (0.3%) | 142 (12%) | |
| No | n (%) | 436 (83%) | 2323 (100%) | 1091 (88%) | |
| Missing or review A pending | n | 20 | 15 | 604 | |
| Chronic liver disease | 3722 | ||||
| Yes | n (%) | 44 (8.4%) | 181 (9.2%) | 84 (6.8%) | |
| No | n (%) | 480 (92%) | 1788 (91%) | 1145 (93%) | |
| Missing or Review A pending | n | 20 | 377 | 608 | |
| Rheumatological/immunological disease | 4053 | ||||
| Yes | n (%) | 32 (6.1%) | 219 (9.5%) | 60 (4.9%) | |
| No | n (%) | 492 (94%) | 2075 (90%) | 1175 (95%) | |
| Missing or review A pending | n | 20 | 52 | 602 | |
| Diabetes mellitus | 4001 | ||||
| Yes | n (%) | 110 (21%) | 101 (4.5%) | 266 (21%) | |
| No | n (%) | 418 (79%) | 2129 (95%) | 977 (79%) | |
| Missing or review A pending | n | 16 | 116 | 594 | |
| Solid tumor disease | 4092 | ||||
| Yes | n (%) | 57 (11%) | 39 (1.7%) | 150 (12%) | |
| No | n (%) | 478 (89%) | 2294 (98%) | 1074 (88%) | |
| Missing or review A pending | n | 9 | 13 | 613 | |
| Haematological-oncological disease | 4074 | ||||
| Yes | n (%) | 29 (5.5%) | 7 (0.3%) | 63 (5.2%) | |
| No | n (%) | 498 (94%) | 2323 (100%) | 1154 (95%) | |
| Missing or review A pending | n | 17 | 16 | 620 | |
| HIV infection | 3948 | ||||
| Yes | n (%) | 3 (0.6%) | 2 (<0.1%) | 17 (1.5%) | |
| No | n (%) | 473 (99%) | 2336 (100%) | 1117 (99%) | |
| Missing or review A pending | n | 68 | 8 | 703 | |
| Chronic neurological or psychiatric disease | 3997 | ||||
| Yes | n (%) | 81 (15%) | 570 (25%) | 159 (13%) | |
| No | n (%) | 451 (85%) | 1690 (75%) | 1046 (87%) | |
| Missing or review A pending | n | 12 | 86 | 632 | |
| History of organ transplantation | 4106 | ||||
| Yes | n (%) | 56 (10%) | 8 (0.3%) | 60 (4.9%) | |
| No | n (%) | 479 (90%) | 2327 (100%) | 1176 (95%) | |
| Missing or review A pending | n | 9 | 11 | 601 | |
| General symptoms | 3711 | ||||
| Yes | n (%) | 246 (59%) | 1964 (95%) | 979 (80%) | |
| No | n (%) | 172 (41%) | 110 (5.3%) | 240 (20%) | |
| Missing or Review A pending | n | 126 | 272 | 618 | |
| Respiratory symptoms | 3726 | ||||
| Yes | n (%) | 253 (61%) | 1974 (95%) | 979 (80%) | |
| No | n (%) | 165 (39%) | 110 (5.3%) | 245 (20%) | |
| Missing or review A pending | n | 126 | 262 | 613 | |
| Gastrointestinal symptoms | 2626 | ||||
| Yes | n (%) | 93 (22%) | 900 (89%) | 448 (37%) | |
| No | n (%) | 325 (78%) | 110 (11%) | 750 (63%) | |
| Missing or review A pending | n | 126 | 1336 | 639 | |
| Neurological symptoms | 2829 | ||||
| Yes | n (%) | 94 (22%) | 1094 (91%) | 424 (35%) | |
| No | n (%) | 324 (78%) | 110 (9.1%) | 783 (65%) | |
| Missing or review A pending | n | 126 | 1142 | 630 | |
| Other symptoms | 2750 | ||||
| Yes | n (%) | 93 (22%) | 1019 (90%) | 387 (32%) | |
| No | n (%) | 325 (78%) | 110 (9.7%) | 816 (68%) | |
| Missing or review A pending | n | 126 | 1217 | 634 | |
| Asymptomatic | 4012 | ||||
| Yes | n (%) | 4 (0.8%) | 110 (4.9%) | 62 (5.0%) | |
| No | n (%) | 520 (99%) | 2134 (95%) | 1182 (95%) | |
| Missing or review A pending | n | 20 | 102 | 593 | |
| Early outcome | 1800 | ||||
| Discharged home/ambulatory care | n (%) | 413 (79%) | 0 (NA%) | 834 (65%) | |
| Unknown or no change yet | n (%) | 0 (0%) | 0 (NA%) | 185 (14%) | |
| Transferred to or from another facility | n (%) | 47 (9.0%) | 0 (NA%) | 107 (8.4%) | |
| Deceased | n (%) | 62 (12%) | 0 (NA%) | 152 (12%) | |
| Missing or review A pending | n | 22 | 2346 | 559 | |
| 3M follow-up conducted | 1258 | ||||
| Yes | n (%) | 162 (69%) | 0 (NA%) | 534 (52%) | |
| No | n (%) | 74 (31%) | 0 (NA%) | 488 (48%) | |
| Missing or review A pending | n | 308 | 2346 | 815 | |
| 6M follow-up conducted | 182 | ||||
| Yes | n (%) | 113 (62%) | 0 (NA%) | 0 (NA%) | |
| No | n (%) | 69 (38%) | 0 (NA%) | 0 (NA%) | |
| Missing or review A pending | n | 362 | 2346 | 1837 | |
| 12M follow-up conducted | 694 | ||||
| Yes | n (%) | 37 (35%) | 0 (NA%) | 219 (37%) | |
| No | n (%) | 68 (65%) | 0 (NA%) | 370 (63%) | |
| Missing or review A pending | n | 439 | 2346 | 1248 |
SUEP, cross-sectoral platform; HAP, high-resolution platform; POP, population-based platform
Baseline characteristics for the SUEP and the HAP correspond to the baseline visit during acute infection, for the POP to the first baseline visit 6-12 months after infection